| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/21548331.2015.998157 |
| P698 | PubMed publication ID | 25559350 |
| P2093 | author name string | Alpesh Amin | |
| Steven Deitelzweig | |||
| P2860 | cites work | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 |
| A new equation to estimate glomerular filtration rate | Q24651973 | ||
| Guidelines on oral anticoagulation with warfarin - fourth edition | Q28240666 | ||
| Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
| Emergency hospitalizations for adverse drug events in older Americans | Q28253788 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society | Q29614693 | ||
| 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association | Q29614695 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Edoxaban versus warfarin in patients with atrial fibrillation | Q29620669 | ||
| Apixaban metabolism and pharmacokinetics after oral administration to humans | Q33373622 | ||
| Genetic risk factors for major bleeding in patients treated with warfarin in a community setting | Q33792352 | ||
| Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size | Q33888401 | ||
| A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey | Q34105149 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| American Heart Association/American College of Cardiology Foundation guide to warfarin therapy | Q34196283 | ||
| Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects | Q34285711 | ||
| Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor | Q34381344 | ||
| Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study | Q34540479 | ||
| Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate | Q34557258 | ||
| Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers | Q34615829 | ||
| Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study | Q34617523 | ||
| Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers | Q34620374 | ||
| Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial | Q34624280 | ||
| Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials | Q34636938 | ||
| European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation | Q34651051 | ||
| Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. | Q34653407 | ||
| Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism | Q34655742 | ||
| Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update | Q34719264 | ||
| Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism | Q34746681 | ||
| Dabigatran versus warfarin in the treatment of acute venous thromboembolism | Q35016336 | ||
| Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752584 | ||
| Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. | Q36336046 | ||
| Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies | Q37363885 | ||
| Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration | Q37738786 | ||
| Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? | Q37968617 | ||
| Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials | Q38183305 | ||
| Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis | Q38439334 | ||
| Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis | Q38439752 | ||
| One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events | Q39428208 | ||
| Prevalence of clinical venous thromboembolism in the USA: current trends and future projections | Q39790131 | ||
| Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model | Q40765852 | ||
| Warfarin use among patients with atrial fibrillation | Q41669384 | ||
| Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects | Q41904888 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Warfarin therapy in patients with venous thromboembolism: Patterns of use and predictors of clinical outcomes | Q42948654 | ||
| Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study | Q43137255 | ||
| Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale | Q43138658 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation | Q43451566 | ||
| Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated | Q43502208 | ||
| Oral apixaban for the treatment of acute venous thromboembolism | Q43741993 | ||
| Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. | Q44405113 | ||
| Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial | Q44725113 | ||
| Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study | Q45343563 | ||
| Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran | Q46045990 | ||
| Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans | Q46131621 | ||
| Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range | Q46173062 | ||
| Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects | Q46835939 | ||
| Extended use of dabigatran, warfarin, or placebo in venous thromboembolism | Q46848170 | ||
| The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans | Q46897672 | ||
| Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. | Q48609772 | ||
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. | Q49168967 | ||
| Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. | Q50501245 | ||
| Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. | Q50697459 | ||
| Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. | Q51328729 | ||
| Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. | Q51361611 | ||
| Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. | Q51368043 | ||
| Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. | Q53100422 | ||
| Effective elimination of dabigatran by haemodialysis | Q56987261 | ||
| Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment | Q57313061 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulation | Q63279445 |
| P304 | page(s) | 1-12 | |
| P577 | publication date | 2015-01-06 | |
| P1433 | published in | Hospital Practice | Q5908551 |
| P1476 | title | Target-specific oral anticoagulants and the hospitalist | |
| P478 | volume | 43 |
| Q85504135 | Recent Publications by Ochsner Authors | cites work | P2860 |
Search more.